Novo Nordisk (NOVOB.DK) shares are gaining 3.0% after the company raised its sales forecast for 2023 on strong demand for Ozempic and Wegovy medicines.
- Operating profit at constant exchange rates +40% to +46%, previously expected +31% to +37%, Bloomberg estimated +37.5%
- Sales at constant exchange rates +32% to +38%, previously expected +27% to +33%, Bloomberg estimated +31.7%.
Morning Wrap (08.01.2026)
Daily summary: Alphabet shares support sentiments on Wall Street 🗽Oil, precious metals and crypto slide
Critical Metals at the center of speculation around Greenland 🔎
US Open: Nasdaq continue to climb📈Intel and Eli Lilly stocks surge